Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial
Short- and mid-term outcomes of TAVR for nonagenarian (>90 years) patients in the PARTNER-1 trial were assessed for 531 pts. MACE occurred in 35% including stroke in 3.6%. Important paravalvular leak occurred in 1.4%. 30-day mortality was 4% and 3-year mortality was 48%, which compared to 44% in a matched population. QOL stabilized at 6 months and was better than preop. A trans-apical approach had a higher risk of 30-day and 3-year mortality.
0
0 comments